Literature DB >> 15805292

RNA interference targeting aurora kinase a suppresses tumor growth and enhances the taxane chemosensitivity in human pancreatic cancer cells.

Tatsuo Hata1, Toru Furukawa, Makoto Sunamura, Shinichi Egawa, Fuyuhiko Motoi, Noriyuki Ohmura, Tomotoshi Marumoto, Hideyuki Saya, Akira Horii.   

Abstract

AURKA/STK15/BTAK, the gene encoding Aurora A kinase that is involved in the regulation of centrosomes and segregation of chromosomes, is frequently amplified and overexpressed in various kinds of human cancers, including pancreatic cancer. To address its possibility as a therapeutic target for pancreatic cancer, we employed the RNA interference technique to knockdown AURKA expression and analyzed its phenotypes. We found that the specific knockdown of AURKA in cultured pancreatic cancer cells strongly suppressed in vitro cell growth and in vivo tumorigenicity. The knockdown induced the accumulation of cells in the G(2)-M phase and eventual apoptosis. Furthermore, we observed a synergistic enhancement of the cytotoxicity of taxanes, a group of chemotherapeutic agents impairing G(2)-M transition, by the RNA interference-mediated knockdown of AURKA. These results indicate that inhibition of AURKA expression can result in potent antitumor activity and chemosensitizing activity to taxanes in human pancreatic cancer.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15805292     DOI: 10.1158/0008-5472.CAN-04-3981

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  87 in total

1.  Aurora A inhibitor (MLN8237) plus vincristine plus rituximab is synthetic lethal and a potential curative therapy in aggressive B-cell non-Hodgkin lymphoma.

Authors:  Daruka Mahadevan; Amy Stejskal; Laurence S Cooke; Ann Manziello; Carla Morales; Daniel O Persky; Richard I Fisher; Thomas P Miller; Wenqing Qi
Journal:  Clin Cancer Res       Date:  2012-02-28       Impact factor: 12.531

2.  Driver mutations: a roadmap for getting close and personal in pancreatic cancer.

Authors:  Murray Korc
Journal:  Cancer Biol Ther       Date:  2010-09-24       Impact factor: 4.742

3.  Novel genes implicated in embryonal, alveolar, and pleomorphic rhabdomyosarcoma: a cytogenetic and molecular analysis of primary tumors.

Authors:  Myriam Goldstein; Isaac Meller; Josephine Issakov; Avi Orr-Urtreger
Journal:  Neoplasia       Date:  2006-05       Impact factor: 5.715

4.  Elucidation of the relationship of BNIP3 expression to gemcitabine chemosensitivity and prognosis.

Authors:  Masaharu Ishida; Makoto Sunamura; Toru Furukawa; Masanori Akada; Hiroko Fujimura; Emiko Shibuya; Shinichi Egawa; Michiaki Unno; Akira Horii
Journal:  World J Gastroenterol       Date:  2007-09-14       Impact factor: 5.742

5.  Inhibition of Aurora A Kinase in Combination with Chemotherapy Induces Synthetic Lethality and Overcomes Chemoresistance in Myc-Overexpressing Lymphoma.

Authors:  Steven I Park; Carolina P Lin; Natalie Ren; Steven P Angus; Dirk P Dittmer; Michael Foote; Trevor Parton; Aadra P Bhatt; Yuri D Fedoriw; Daniel P Roth; Marissa L Cann; Gary L Johnson; Blossom Damania
Journal:  Target Oncol       Date:  2019-10       Impact factor: 4.493

Review 6.  New combination therapies with cell-cycle agents.

Authors:  Gagan Deep; Rajesh Agarwal
Journal:  Curr Opin Investig Drugs       Date:  2008-06

Review 7.  Target validation and biomarker identification in oncology : the example of aurora kinases.

Authors:  Riccardo Colombo; Jürgen Moll
Journal:  Mol Diagn Ther       Date:  2008       Impact factor: 4.074

8.  Aurora-A phosphorylates, activates, and relocalizes the small GTPase RalA.

Authors:  Kian-Huat Lim; Donita C Brady; David F Kashatus; Brooke B Ancrile; Channing J Der; Adrienne D Cox; Christopher M Counter
Journal:  Mol Cell Biol       Date:  2009-11-09       Impact factor: 4.272

9.  Taxane-mediated radiosensitization derives from chromosomal missegregation on tripolar mitotic spindles orchestrated by AURKA and TPX2.

Authors:  M Orth; K Unger; U Schoetz; C Belka; K Lauber
Journal:  Oncogene       Date:  2017-09-04       Impact factor: 9.867

10.  Preclinical characterization of Aurora kinase inhibitor R763/AS703569 identified through an image-based phenotypic screen.

Authors:  John McLaughlin; Vadim Markovtsov; Hui Li; Steve Wong; Marina Gelman; Yanhong Zhu; Christian Franci; D Wayne Lang; Erlina Pali; Joe Lasaga; Caroline Low; Feifei Zhao; Betty Chang; Tarikere L Gururaja; Weiduan Xu; Muhammad Baluom; David Sweeny; David Carroll; Arvinder Sran; Sambaiah Thota; Manjeet Parmer; Angela Romane; George Clemens; Elliott Grossbard; Kunbin Qu; Yonchu Jenkins; Taisei Kinoshita; Vanessa Taylor; Sacha J Holland; Ankush Argade; Rajinder Singh; Polly Pine; Donald G Payan; Yasumichi Hitoshi
Journal:  J Cancer Res Clin Oncol       Date:  2010-01       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.